SOAR phase 2 trial: PSMA-directed salvage therapy without ADT feasible in oligorecurrent prostate cancer

Phase 1-2 · UroToday · 2026-10-02. Number 5 in the UrologyWatch Top 5 for October 5, 2026.

The SOAR phase 2 trial evaluated PET-defined metastasis-directed therapy without androgen deprivation in men with oligorecurrent prostate cancer, reporting on feasibility and outcomes of this ADT-sparing approach.

Why it matters: Adds phase 2 data on an ADT-sparing approach for selected oligorecurrent patients; randomized confirmation is still needed.

Source: UroToday · PubMed 42812884 · DOI 10.1097/ju9.0000000000000517

The full October 5, 2026 edition · Today's urology news